Anti neuroinflammatory effect of Vildagliptin in ischaemia-reperfusion induced cerebral infarction in normal and STZ induced type-II diabetic rats
Diabetes is one of the major risk factor for cerebral ischemic stroke. Increased base line levels of oxidative stress in diabetes will lead to cerebral ischemic damage. In pathological conditions such as cerebral ischemia/reperfusion injury, free radicals cause oxidative stress and inflammation leading to increased injury of brain. Inflammation is one of the major pathological mechanisms involved in cerebral ischemia and reperfusion injury. Vildagliptin newer anti-diabetic drug of the class DPP-4 inhibitors is reported to have anti-inflammatory properties apart from its antihyperglycemic activity. Therefore the aim of the present study is to evaluate the anti-inflammatory effect of Vildagliptin against cerebral infarction induced ischemia reperfusion injury in normal and STZ induced diabetic Wistar rats. Cerebral infarction was induced by bilateral common carotid artery occlusion followed by 4 hr reperfusion. Percent infarction, inflammatory markers such as MPO, TNF-?, IL-6 and IL-10 were analysed. Treatment with Vildagliptin for a period of four weeks produced significant reduction in percent cerebral infarct volume. Vildagliptin at 10 mg/kg dose, showed significant reduction in markers like MPO, TNF-?, IL-6 and IL-1? in diabetic group when compared to normal group and in contrast significant increase in anti-inflammatory marker like IL-10 levels. Vildagliptin showed significant cerebroprotective effect by antiinflammatory mechanisms.
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, et al: Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation 2014; 129:e28e292.
Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H, American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology: Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44:870947.
Cade, W. T. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Physical therapy. 2008; 88(11):1322-1335.
Elneihoum AM, Goransson M, Falke P, Janzon L. Three-year survival and recurrence after stroke in Malmo, Sweden: an analysis of stroke registry data. Stroke. 1998; 29:21142117.
Jiang, M., Li, J., Peng, Q., Liu, Y., Liu, W., Luo, C., & Mo, Z. Neuroprotective effects of bilobalide on cerebral ischemia and reperfusion injury are associated with inhibition of pro-inflammatory mediator production and down-regulation of JNK1/2 and p38 MAPK activation. Journal of neuroinflammation, 2014; 11(1), 1-17.
Lenardo MJ, Baltimore D. NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell. 1989; 58:227229.
Liao SL, Chen WY, Raung SL, Kuo JS, Chen CJ. Association of immune responses and ischemic brain infarction in rat. Neuroreport. 2001; 12:19431947.
Lambertsen KL, Biber K, Finsen B. Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab. 2012; 27:122.
Yang G, Ham I, Choi HY. Anti-inflammatory effect of prunetin via the suppression of NF-?B pathway. Food Chem Toxicol. 2013; 58:124132.
Sarkar, S., Fekete, C., Legradi, G., Lechan, R.M., Glucagon like peptide-1 (736) amide (GLP-1) nerve terminals densely innervate corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Brain Res. 2003; 985:163168.
Baggio, L.L., Drucker, D.J., Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132:21312157.
Hocher, B., Reichetzeder, C., & Alter, M. L. Renal and cardiac effects of DPP-4 inhibitorsfrom preclinical development to clinical research. Kidney and Blood Pressure Research, 2012; 36(1):65-84.
Rizzo, M. R., Barbieri, M., Marfella, R., & Paolisso, G. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes Role of dipeptidyl peptidase-IV inhibition. Diabetes care. 2012; 35(10):2076-2082.
Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011; 124:2338 2349.
Briyal, S., Gulati, K., & Gulati, A. Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats. Brain research 2012; 1427:23-34.
Bederson JB, Pitts LH, Tsuji M et al. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1996; 17:472 476.
Spencer, E.A., Pirie, K.L., Stevens, R.J., Beral, V., Brown, A., Liu, B., Green, J., Reeves, G.K.,. Diabetes and modifiable risk factors for cardiovascular disease: the prospective Million Women Study. Eur. J. Epidemiol. 2008; 23:793799.
Lindsberg, P.J., Roine, R.O. Hyperglycemia in acute stroke. Stroke 2004; 35: 363364.
Huang J, Upadhyay UM, Tamargo RJ. Inflammation in stroke and focal cerebral ischemia. Surg Neurol.2006; 66:232245.
Orsu, P., Murthy, B. V. S. N., & Akula, A. Cerebroprotective potential of resveratrol through anti-oxidant and anti-inflammatory mechanisms in rats. Journal of Neural Transmission 2013; 120(8):1217-1223.
Biswas, S.C., Buteau, J., Greene, L.A., Glucagon-like peptide-1 (GLP-1) diminishes neuronal degeneration and death caused by NGF deprivation by suppressing Bim induction. Neurochem. Res. 2008; 33:18451851.
Copyright (c) 2016 International Journal of Pharmacological Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- Author must Submit Copyright form After acceptance of Article